ABSTRACT: Background. The local-regional failure of advanced oral squamous cell carcinoma (OSCC) after surgery results from the regrowth of residual tumor cells that may be stimulated by epidermal growth factor receptor (EGFR) ligands during the wound healing process. Methods. The level of EGFR ligands in human drain fluids (DFs) from OSCC resection and remote flap donor site were determined. A mouse model of microscopic residual OSCC was established and treated with cetuximab to measure tumor growth, survival, and cervical lymph node metastases. A mouse model of wound healing was also established to assess the effect of an EGFR antibody on the wound healing process.
INTRODUCTION
Patients with oral squamous cell carcinoma (OSCC) still have a poor prognosis with a current 5-year survival of only 50%, despite advances in surgery and radiation therapy (RT). 1 One of the most critical prognostic parameters is local-regional failure, which can occur in up to 50% of patients. [2] [3] [4] Although the current standard of care for patients with local-regionally advanced OSCC is surgery and postoperative RT (PORT), administered along with chemotherapy, the local-regional failure rate for patients with OSCC can exceed 50% for high-risk patients despite maximally tolerated doses of PORT and chemotherapy. 5 Postoperative local-regional failure results from residual tumor cells that were not expunged by treatment. 6 Typically, the time interval between surgery and PORT is 4 to 8 weeks to allow for healing and recovery, 6 but during this interval, residual tumor cells may repopulate in the growth factor-rich wound. [6] [7] [8] [9] [10] [11] Thus, surgery itself may induce the expression of growth factors such as epidermal growth factor (EGF) and related ligands that can stimulate the growth of residual tumor cells. 9 For the treatment of residual disease, the use of PORT has been practiced for several decades, and the incorporation of concurrent chemotherapy to maximally tolerated doses is supported by data from 2 large randomized trials. 12, 13 However, residual tumor cells are thought to have limited response to adjuvant therapy and poorer local-regional control. 14, 15 To address this concern, an "early intervention'' clinical trial, Radiation Therapy Oncology Group (RTOG)-0024, using early postoperative chemotherapy followed by concurrent chemoradiotherapy after surgical resection of high-risk head and neck squamous cell carcinoma (HNSCC) was conducted, and this strategy was found to be both feasible and tolerable. 6 The epidermal growth factor receptor (EGFR) pathway plays an important role in the regulation of cellular proliferation, differentiation, and survival. 16 This receptor is overexpressed in more than 90% of HNSCC specimens, 17 and a higher level of EGFR expression is associated with reduced survival. [18] [19] [20] Therefore, EGFR-targeted treatment strategies have been developed and have shown to be effective in treating patients with HNSCC. The most widely studied EGFR targeting agent is cetuximab (Erbitux, ImClone Systems), an anti-EGFR monoclonal antibody that is approved by the Food and Drug Administration for the treatment of patients with HNSCC. [21] [22] [23] Cetuximab has also been found in a recent study to inhibit the growth of cultured head and neck cancer cells that are stimulated by the addition of surgical wound catheter drainage fluid from patients with head and neck cancer. 10 Therefore, we have hypothesized that EGF and transforming growth factor (TGF)-a are present in the wounds of patients who have undergone resection of head and neck cancers and could be stimulating the early repopulation of residual tumor cells and that inhibition of EGFR signaling in this setting could inhibit this tumor regrowth and thereby improve treatment outcomes.
In the present study, we sought to evaluate the levels of the EGF and TGF-a in drainage fluids from patients with head and neck surgery and determined whether cetuximab, an anti-EGFR monoclonal antibody, can inhibit tumor progression and recurrence in an in vivo OSCC model of postoperative microscopic residual disease and how cetuximab affects surgical wound healing.
MATERIALS AND METHODS
Wound drainage fluids from patients with oral squamous cell carcinoma
Wound drainage fluids were collected in accord with a protocol approved by the Institutional Review Board at The University of Texas MD Anderson Cancer Center. Informed consent was provided from each patient, in accord with the Declaration of Helsinki. We collected paired samples of wound drainage fluids 1 to 3 days postoperatively from the cancer operative bed and the free flap donor site in 11 patients with SCC of the oral tongue and/or floor of mouth who underwent cancer resection and free flap reconstruction.
Human cytokine assay
The human cytokine/chemokine Milliplex MAP kit (Millipore, Bedford, MA) was used to test samples for the presence of EGF and TGF-a. Briefly, 25 lL of anticytokine antibody-labeled beads (prepared in Millipore assay buffer) were added to each well of a 96-well plate and washed twice with Millipore wash buffer. Samples (25 lL/well) or standards (25 lL/well) were then added to each well, and the plate was sealed before shaking and left overnight at 4 C. The wells were washed 2 times in Millipore wash buffer, and, as before, 25 lL of detection antibody was added to each well and the plate was sealed and incubated for 1 hour at room temperature. After 2 more washes in Millipore wash buffer, 25 lL of streptavidin-phycoerythrin was added to each well and the plate sealed and incubated for 30 minutes at room temperature. The plate was then washed 2 times in Millipore wash buffer and the beads resuspended in 150 lL of sheath fluid (Luminex Corporation, Austin, TX). Samples were loaded into the Bio-Rad Bio Plex system machine (Bio-Rad Laboratories, Hercules, CA) and the cytokine concentration in each sample was calculated automatically from a 5PL standard curve using the BioPlex Manager software version 5.0 (Bio-Rad Laboratories).
Animals and maintenance
Eight-to 12-week-old male athymic nude mice and BALB/c male mice were purchased from the National Cancer Institute (Bethesda, MD). Athymic nude mice were used for the microscopic residual disease model, and BALB/c mice were used for the wound-healing model. The mice were kept in a specific pathogen-free facility and were fed irradiated mouse chow and autoclaved reverse osmosis-treated water. The facilities were approved by the American Association for Accreditation of Laboratory Animal Care and met all current regulations and standards of the U.S. Department of Agriculture, the U.S. Department of Health and Human Services, and the National Institutes of Health. Animal procedures were done in accord with a protocol approved by the Institutional Animal Care and Use Committee of MD Anderson Cancer Center.
Cell lines and reagents
The OSC-19 cell line, established in Japan from a cervical lymph node metastatic tumor of a patient with well-differentiated SCC of the tongue, 24 was used in the study. OSC-19 cells were retrovirally infected with the green fluorescent protein and the luciferase gene (OSC-19-luc), as described previously. 25 The murine SCC7 cell line is a rapidly dividing squamous cell carcinoma that spontaneously arose from the skin of a C3H/HeJ mouse. 26 Cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, Lglutamine, sodium pyruvate, nonessential amino acids, and vitamin solution. Adherent monolayer cultures were maintained on plastic plates and incubated at 37 C in 5% carbon dioxide and 95% oxygen. The cultures were Mycoplasma-free and maintained for no longer than 12 weeks after they were recovered from frozen stocks. Cetuximab (C225/Erbitux) and rat-antimouse EGFR antibody (ME-1) were provided by Imclone (New York, NY).
An in vivo model of microscopic residual disease of oral squamous cell carcinoma
To establish an in vivo model of microscopic residual disease of OSCC, 5 Â 10 3 of OSC-19-luc cells were suspended in 30 lL of serum-free DMEM and injected into the tongues of athymic nude mice, as described previously. 27 Tumor growth was monitored by bioluminescence imaging every 7 to 8 days using Living Image software 3.2 (Xenogen, Alameda, CA), as described previously. 25 Animals were first imaged 3 days after cell inoculation and then a partial thickness incision of the anterolateral tongue at the site of the previous tumor cell injection was made to simulate a postoperative wound bed harboring microscopic-only residual cancer cells. The mice were then randomized into 2 groups to receive either phosphate-buffered saline (PBS) as placebo (n ¼ 10) or cetuximab (n ¼ 15) by intraperitoneal injection twice per week for 3 weeks.
We euthanized mice by CO 2 asphyxiation 90 days after the injection of OSC-19-luc cells, or sooner if they lost more than 20% of their preinjection body weight or became moribund. The mouse tumors were resected and fixed in formalin and embedded in paraffin for immunohistochemical and hematoxylin-eosin staining. Cervical lymph nodes were also resected, embedded in paraffin, sectioned, stained with hematoxylin-eosin, and evaluated for metastases.
Western blotting SCC7 cells were plated and incubated in DMEM with 10% fetal bovine serum overnight. The next day, cells were washed with PBS and incubated in serum-free DMEM for 24 hours. Cells were then treated for 120 minutes with 0-100 nM ME-1. Next, EGF (50 ng/mL) was added for 15 minutes, after which the cells were washed in chilled (4 C) PBS and the plates kept on ice. Total cell lysates were obtained and subjected to Western blot analysis, as previously described. 28 The membranes were blocked for 1 hour at room temperature with 5% bovine serum albumin in 0.1% Tween 20 in tris-buffered saline and incubated overnight at 4 C in anti-EGFR (1:500; Upstate Biotechnology, Lake Placid, NY) or anti-phospho-EGFR (1:500; Cell Signaling, Beverly, MA) in the membrane-blocking solution described above. Next, the membranes were washed with Tween 20 in tris-buffered saline and incubated for 1 hour at room temperature in horseradish peroxidase-conjugated antirabbit immunoglobulin G (Santa Cruz Biotechnology, Santa Cruz, CA) to detect EGFR and phospho-EGFR. Membranes were then analyzed using the SuperSignal West chemiluminescent system (Pierce Biotechnology, Rockford, IL). To verify equal loading of proteins, membranes were stripped and reprobed with anti-b-actin (1:5000).
Wound healing mouse model
To see the effect of EGFR inhibition on wound healing, we established a wound healing mouse model. BALB/C mice were anesthetized by intraperitoneal injection of pentobarbital 50 mg/kg, and the hair on the back was shaved. First, 5 mm full-thickness incisions were made in the skin of the dorsum of the mouse using a sterile biopsy punch. The incision was placed between the shoulder blades of the mouse to prevent the mouse from reaching the wound and then was closely inspected and any bleeding stopped using electrocautery. The animals were randomized to receive either ME-1 (40 mg/kg) or PBS as placebo by intraperitoneal 3 times a week. For histological assessment of the quality of wound healing, the wound edges were closed with 5-0 vicryl surgical suture (Ethicon, Somerville, NJ) and the wounds were excised on 3, 7, 14, and 21 days, and fixed in 10% formalin. Fixed skin samples were embedded in paraffin, and 10-lm sections were prepared, mounted, and stained with hematoxylin-eosin. Histologic sections from each wound were analyzed and graded by a pathologist who was blinded as to the identity of each sample. Histological assessment was done using a grading scale for the quality of inflammation (grade 0, no inflammation; grade 1, mild; grade 2, mild to moderate; grade 3, moderate; and grade 4, severe) and fibrosis (grade 0, no fibrosis; grade 1, mild; grade 2, moderate; and grade 3, prominent), as described previously. 29 To assess the effect of EGFR inhibition on wound healing, wound size was measured with microcalipers twice a week until complete wound closure.
Statistical analysis
Quantitative data for the presence of cytokines and from histological assessment for inflammation and fibrosis were compared using unpaired t tests. The Fisher exact test was used to analyze associations between treatment groups and tumor formation or cervical lymph node metastases. The time to wound closure in the control group was compared with that in the ME-1 treatment group using the 2-tailed t tests. The Fisher exact test was used to analyze associations between treatment groups and incidence of cervical lymph node metastases and tumor formation. Overall survival and disease-free survival were analyzed by the Kaplan-Meier method and compared using log-rank tests. Analysis was performed with Prism 5.01 software (GraphPad Software, San Diego, CA). For all comparisons, p < .05 was considered statistically significant.
RESULTS
Epidermal growth factor receptor ligands are increased in drain fluids from head and neck surgical resection beds
To determine whether tissue factors are released in the postsurgical wound that could stimulate residual tumor cells at the resection site (ie, microscopic residual disease), secreted fluid was harvested postoperatively from wound catheters at the head and neck cancer resection site. The concentrations of EGF and TGF-a in drain fluids (DFs) from the head and neck cancer resection and control flap donor sites were determined using a fluorescence-based multiplex bead immunoabsorption assay (Figure 1) . The median concentration of TGF-a (53.0 pg/ mL) was significantly higher in DF from the resection sites than in DF from the flap donor sites (27.5 pg/mL; p ¼ .0106). The concentration of EGF was also higher in DF from the resection sites (median, 434.3 pg/mL) compared with DF from the flap donor site (median, 196.8 pg/mL), but the difference did not reach statistical significance (p ¼ .0710).
Cetuximab inhibits tumor formation and growth and prolongs overall and disease-free survival in an in vivo model of microscopic residual disease
The finding of elevated levels of EGF and TGF-a in the wounds of patients with OSCC led us to hypothesize that inhibition of EGF and TGF-a signaling in a minimal residual disease model could inhibit tumor outgrowth and prolong animal survival. Microscopic residual disease is the most likely source of local and/or regional recurrence after surgery in patients treated for OSCC after surgery. Therefore, we established an in vivo model of microscopic residual disease of OSCC. Groups of mice in which OSC-19-luc cells were implanted in the minimal residual model were treated with either cetuximab or placebo and the bioluminescence intensity of OSC-19-luc cells was monitored to measure the effect of cetuximab treatment. A reduction of bioluminescence of OSC-19-luc cells was observed in the cetuximab treatment group compared with the control group (Figures 2A-2D ) in our in vivo OSCC model of microscopic residual disease. As shown in Figure 2E , the mean survival durations for the control and cetuximab groups were 86.5 days and 90.0 days, respectively (p ¼ .0020, log-rank test). Mice with bioluminescence intensities less than 1 Â 10 5 photons/ second were classified as disease-free. As shown in Figure 2F , the mean disease-free survival periods for the control and cetuximab groups were 73.0 days and 90.0 days, respectively, thus, cetuximab treatment also significantly prolonged the disease-free period compared with the placebo (p ¼ .0100, log-rank test). Consistently, tumor formation in mice treated with cetuximab was inhibited significantly in comparison to the control group (50.0% vs 6.7%, respectively; p ¼ .0225; Figure 3A) . Similarly, fewer regional metastases were observed in the cetuximab treatment group than in the control group (40% vs 6.7%, respectively; p ¼ .125; Figure 3B ).
Inhibition of murine epidermal growth factor receptor results in only minor delay of reepithelialization and no appreciable difference in the degree of inflammation or fibrosis in the mouse wound healing model
Although the presence of EGF and TGF-a in OSCC resection wounds, and the favorable response of OSCC cells to cetuximab treatment in a microscopic residual disease model, indicate that early treatment of patients with OSCC after surgery could potentially decrease the incidence and severity of local and/or regional recurrence, there is some concern that cetuximab therapy may also inhibit wound healing in the postsurgical patient, because EGF and TGF-a are thought to be involved in postoperative wound healing. 30 To address whether cetuximab would adversely affect wound healing, we first determined whether ME-1, a rat-antimouse EGFR monoclonal antibody, inhibits the phosphorylation of EGFR in murine cells. We found that ME-1 suppressed EGF-stimulated phosphorylation of the EGFR in a dose-dependent manner, whereas the total expression of the nonphosphorylated kinase remained unchanged ( Figure 4A ).
We next examined the effect of EGFR inhibition with ME-1 on wound-healing; wounded mice were treated with either placebo or ME-1 and then the size of the wound was measured over time. As shown in Figure 4B and 4C, we observed that the decrease in the mean wound sizes of mice in the ME-1 group was delayed slightly compared with that of mice in the control group, but the difference was not statistically significant (p ¼ .2099).
Histological assessments of wounds from ME-1 and placebo-treated mice at different time points were also carried out to determine the effect of EGFR inhibition on fibrosis and inflammation during wound healing ( Figures  4D, 4E , and 4F). Although hematoxylin-eosin staining detected a minor increase in inflammation and fibrosis in the ME-1 treatment group compared with the control group, the differences were not significant (p ¼ .1518 and p ¼ .1879, respectively).
DISCUSSION
In this study, we confirmed the presence of elevated levels of EGFR ligands in OSCC surgical wound beds but not in flap donor site wounds using human wound drainage fluid samples. We demonstrated that cetuximab inhibited tumor progression in an in vivo model of microscopic residual disease and that the use of a rat-anti mouse EGFR antibody does not significantly delay the process of wound healing in a mouse wound healing model. Taken together, our results demonstrate in a preclinical model that intervention in the EGFR pathway with cetuximab treatment soon after surgery could inhibit the repopulation of OSCC cells without impairing wound healing.
The EGFR pathway plays an important role in the regulation of the cellular proliferation, differentiation, and survival of HNSCC. 16 The EGFR ligands, EGF and TGF-a bind to EGFR, resulting in the stimulation and activation of signaling complexes, leading to cell cycle progression, reduced apoptosis, angiogenesis, and metastatic potential. 31 Growth factors such as EGF and TGF-a also play key roles in initiating and sustaining the phases of tissue repair in the wound healing process. 32, 33 It has been reported that early-phase DF contains high concentrations of EGF. 34 A recent study also showed that elevated levels of wound drainage catheter fluid from patients with head and neck cancer can stimulate the growth of head and neck tumor cells in culture, and that this growth stimulation can be inhibited in vitro by the addition of cetuximab. 10 Thus, the release of growth factors such as EGFR ligands induced by surgery to remove the primary tumor and subsequent wound healing might trigger the development and/or progression of microscopic residual HNSCC. 9, 35 In the present study, we observed the elevated levels of EGF and TGF-a in wound DF from head and neck surgeries consistent with the findings of previous reports. The levels of EGF and TGF-a were higher in wound DF from head and neck surgery sites than from lower-extremity flap donor sites in samples from the same patients. The most likely explanation for this finding is that the source of this cytokine is arising from the microscopic residual tumor cells or a host response to them. A possible alternative explanation is the close proximity of the oral cavity and the neck wound that may be contiguous or communicate during the cancer resection or early recovery interval. This is supported by evidence that elevated levels of human salivary EGF have been found after surgery. 36 We also found that the concentration of EGF in oral saliva before the head and neck surgical procedure was similar to that in the head and neck surgical wound drainage fluid (data not shown). However, the level of TGF-a was significantly higher in DFs from the head and neck surgical wound compared with saliva (data not shown) or flap donor site drainage fluid, suggesting that this cytokine most likely arises from the microscopic residual tumor cells or a host response.
Because advanced HNSCC including OSCC tend to recur local-regionally after surgical removal, postoperative adjuvant treatments are frequently needed to attain local-regional disease control. Tumor recurrence has been traditionally thought to occur as the result of the outgrowth of microscopic residual tumor cells, even in patients with negative surgical margins. However, the surgical resection of a cancer itself may contribute to the recurrence of that cancer through stress-induced immunosuppression 37 and/or growth factors and/or cytokines that are expressed during the wound healing process. 9 Thus, local-regional failure is a serious issue for patients with OSCC 2,4 ; however, there have been no prior animal models that mimic the recurrence of OSCC, even though many animal models of HNSCC have been established so far. 4 Therefore, we established a microscopic disease model for OSCC and then tested our hypothesis that intervention with EGFR inhibitors soon after surgery can suppress the accelerated repopulation of OSCC tumor cells in vivo. In the present study, we have shown that cetuximab inhibits tumor growth and tumor formation and prolongs overall survival and disease-free survival in an in vivo model of microscopic residual OSCC. These findings support that early intervention with EGFR targeted treatment can inhibit local oral tumor growth and regional metastatic disease development in a minimal disease model.
Some have voiced concerns that early intervention could contribute to the delayed healing or the development of wound complications such as pharyngocutaneous fistula leading to increased length of stay, resource utilization, and patient anxiety and morbidity. 38, 39 Dean et al 40 have studied human wound healing following combined radiation and cetuximab therapy in patients with head and neck cancer in a retrospective analysis in which they found that cetuximab did not significantly increase the risk of postsurgical wound complications. Because we did not observe significant inhibition of wound healing in our model in which a monoclonal antibody to murine EGFR, ME-1, was delivered to mice with standardly applied cutaneous wounds, we believe that it is safe to study the treatment of patients with postresection head and neck cancer with EGFR targeted therapy early in the postoperative period within the context of an institutional review board-approved clinical trial. Although we have used cetuximab to inhibit the EGFR pathway in the present study, it is conceivable that EGFR inhibitors such as erlotinib may be also useful for inhibiting postoperative microscopic residual OSCC.
In conclusion, to the best of our knowledge, we are the first to report differential expression of EGFR ligands in OSCC and free flap donor site wound beds as measured in their DFs, that cetuximab inhibits tumor progression in an in vivo model of microscopic residual disease and that postoperative EGFR inhibition does not cause any significant delay of healing in a mouse wound healing model. We contend that inhibition of the EGFR pathway by cetuximab soon after surgery could delay accelerated repopulation of OSCC cells, without causing wound healing problems just before the initiation of external beam radiation therapy. These findings indicate the need for further preclinical and clinical evaluation. 4. The effect of the ME-1 rat-antimouse epidermal growth factor (EGF) antibody in a mouse wound healing model. (A) ME-1 inhibits the phosphorylation of EGFR in the murine oral cancer cell line SCC-7 in vitro. Antibodies to total (unphosphorylated) mouse EGFR and b-actin were used as protein loading controls. (B) The effects of ME-1 treatment on wound healing. A mouse wound healing model was established to determine whether systemic treatment with an EGFR antibody would interfere with wound healing. Wound sizes were measured with microcalipers twice a week. Points represent mean wound size; bars, SE. (C) Effect of ME-1 on wound diameter in a mouse wound healing model. Representative wounds from punch biopsy in each group on days 4, 7, 9, 11, 13, and 18. (D-F) The effect of ME-1 on wound histology in a mouse wound healing model. Mice were randomized to receive treatment with ME-1 (40 mg/kg) or phosphate-buffered saline (PBS) as placebo. The mice were killed on days 3, 7, 14, and 21 of treatment, at which time the wounds were excised and fixed in 10% formalin for histologic evaluation of hematoxylin-eosin staining using light microscopy. (D) Histological assessment for quality of fibrosis. Columns, mean grade of fibrosis; bars, SE. (E) Histological assessment for quality of inflammation. Columns, mean grade of inflammation; bars, SE. (F) Representative micrographs of skin wounds from mice treated with vehicle or ME-1 on day 21. Epithelialization is almost complete but slightly irregular. Original magnification, Â40. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
